1. Shen F, Zhang X, Zhang Y, Ding J, Chen Q. Hormone receptors expression in ovarian cancer taking into account menopausal status: a retrospective study in Chinese population. Oncotarget. 2017;8(48):84019. [
DOI:10.18632/oncotarget.20251] [
PMID] [
PMCID]
2. Ajani MA, Salami A, Awolude OA, Oluwasola AO. Hormone-receptor expression status of epithelial ovarian cancer in Ibadan, South-western Nigeria. Pan Afr Med J. 2017;27:259. [
DOI:10.11604/pamj.2017.27.259.11883] [
PMID] [
PMCID]
3. Chen S, Dai X, Gao Y, Shen F, Ding J, Chen Q. The positivity of estrogen receptor and progesterone receptor may not be associated with metastasis and recurrence in epithelial ovarian cancer. Sci Rep. 2017;7(1):1-7. [
DOI:10.1038/s41598-017-17265-6] [
PMID] [
PMCID]
4. Iqbal N, Iqbal N. Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int. 2014;2014:852748. [
DOI:10.1155/2014/852748] [
PMID] [
PMCID]
5. English DP, Roque DM, Santin AD. HER2 expression beyond breast cancer: therapeutic implications for gynecologic malignancies. Mol Diagn Ther. 2013;17(2):85-99. [
DOI:10.1007/s40291-013-0024-9] [
PMID] [
PMCID]
6. Luo H, Xu X, Ye M, Sheng B, Zhu X. The prognostic value of HER2 in ovarian cancer: a meta-analysis of observational studies. PloS One. 2018;13(1):e0191972. [
DOI:10.1371/journal.pone.0191972] [
PMID] [
PMCID]
7. Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JM, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. Arch Pathol Lab Med. 2018;142(11):1364-82. [
DOI:10.5858/arpa.2018-0902-SA] [
PMID]
8. Herrington CS. WHO Classification of Tumours Female Genital Tumours: International Agency for Research on Cancer; 2020.
9. Elmahdi NM, Latiff LA, Zavare M, Ismail M, Manaf RA, Bin Abu Bakar A. A cross-sectional study of ovarian cancer knowledge and its determinants among female employees in a public University Malaysia. Mal J Med Health Sci. 2017;13:71-9.
10. Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface epithelial tumors of the ovary. Blaustein's pathology of the female genital tract: Springer; 2011. p. 679-784. [
DOI:10.1007/978-1-4419-0489-8_14]
11. Pokhriyal R, Hariprasad R, Kumar L, Hariprasad G. Chemotherapy resistance in advanced ovarian cancer patients. Biomark Cancer. 2019;11:1179299X19860815. [
DOI:10.1177/1179299X19860815] [
PMID] [
PMCID]
13. Nucci MR, Parra-Herran C. Gynecologic Pathology E-Book: A Volume in the Series: Foundations in Diagnostic Pathology: Elsevier Health Sciences; 2019.
17. Seidman JD, Horkayne-Szakaly I, Haiba M, Boice CR, Kurman RJ, Ronnett BM. The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin. Int J Gynecol Pathol. 2004;23(1):41-4. [
DOI:10.1097/01.pgp.0000101080.35393.16] [
PMID]
18. Ho C. Pattern of ovarian tumours among Malaysian women at General Hospital~ Kuala Lumpur. Med J Malaysia. 1992;47(2):139-46.
19. Lindgren PR, Cajander S, Bäckström T, Gustafsson J-Å, Mäkelä S, Olofsson JI. Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol. 2004;221(1-2):97-104. [
DOI:10.1016/j.mce.2004.02.020] [
PMID]
20. Abu-Jawdeh G, Jacobs T, Niloff J, Cannistra S. Estrogen receptor expression is a common feature of ovarian borderline tumors. Gynecol Oncol. 1996;60(2):301-7. [
DOI:10.1006/gyno.1996.0043] [
PMID]
21. Agarwal N, Rao D, Murgeshan K, Verma U, Mittal S, Buckshee K, Chapeker T. Clinical evaluation of steroid receptors in ovarian neoplasms. Int J Gynaecol Obstet. 1987;25(2):145-9. [
DOI:10.1016/0020-7292(87)90009-9] [
PMID]
22. Fujimura M, Hidaka T, Kataoka K, Yamakawa Y, Akada S, Teranishi A, Saito S. Absence of Estrogen Receptor-[alpha] Expression in Human Ovarian Clear Cell Adenocarcinoma Compared With Ovarian Serous, Endometrioid, and Mucinous Adenocarcinoma. Am J Surg Pathol. 2001;25(5):667-72. [
DOI:10.1097/00000478-200105000-00016] [
PMID]
23. Rutherford T, Brown WD, Sapi E, Aschkenazi S, Muñoz A, Mor G. Absence of estrogen receptor-[beta] expression in metastatic ovarian cancer. Obstet Gynecol. 2000;96(3):417-21. https://doi.org/10.1097/00006250-200009000-00018 [
DOI:10.1016/S0029-7844(00)00917-0] [
PMID]
24. Seidman JD, Cho KR, Ronnett BM, Kurman RJ. Surface epithelial tumors of the ovary. Blaustein's pathology of the female genital tract2002.
25. Lindgren PR, Backstrom T, Cajander S, Damber M-G, Mahlck C-G, Zhu D, Olofsson J. The pattern of estradiol and progesterone differs in serum and tissue of benign and malignant ovarian tumors. Int J Oncol. 2002;21(3):583-9. [
DOI:10.3892/ijo.21.3.583] [
PMID]
26. Sylvia MT, Kumar S, Dasari P. The expression of immunohistochemical markers estrogen receptor, progesterone receptor, Her-2-neu, p53 and Ki-67 in epithelial ovarian tumors and its correlation with clinicopathologic variables. Indian J Pathol Microbiol. 2012;55(1):33-7. [
DOI:10.4103/0377-4929.94852] [
PMID]
27. Ayadi L, Chaabouni S, Khabir A, Amouri H, Makni S, Guermazi M, et al. Correlation Between Immunohistochemical Biomarkers Expression and Prognosis of Ovarian Carcinomas in Tunisian Patients. World J Oncol. 2010;1(3):118-28. [
DOI:10.4021/wjon2010.06.213w] [
PMID] [
PMCID]
28. Arias-Pulido H, Smith HO, Joste NE, Bocklage T, Qualls CR, Chavez A, et al. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol Oncol. 2009;114(3):480-5. [
DOI:10.1016/j.ygyno.2009.05.045] [
PMID] [
PMCID]
29. McCaughan H, Um I, Langdon SP, Harrison DJ, Faratian D. HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis. J Clin Pathol. 2012;65(7):670-1. [
DOI:10.1136/jclinpath-2011-200616] [
PMID]
30. Asadinejad E, Abdirad A, Nili F, Soleimani V. HER2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-sectional Study in an Iranian Population and Literature Review. Middle East J Cancer. 2018;9(4):300-9.